| Russell Wayne Dowell, DO | |
|
Vcuhs Dept Of Em Residency/fellowship, 1250 E. Marshall Street, Richmond, VA 23298 | |
| (804) 828-4860 | |
| Not Available |
| Full Name | Russell Wayne Dowell |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | Vcuhs Dept Of Em Residency/fellowship, Richmond, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730703604 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0102207987 (Virginia) | Primary |
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20031208000283 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress. Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C.
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.
› Verified 2 days ago
| Entity Name | Alexandria Springfield Emergency Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740529700 PECOS PAC ID: 1052558954 Enrollment ID: O20200115002186 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress. Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C.
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Russell Wayne Dowell, DO Vcuhs Gmea, Box 980257, Richmond, VA 23298-0257 Ph: (804) 828-9783 | Russell Wayne Dowell, DO Vcuhs Dept Of Em Residency/fellowship, 1250 E. Marshall Street, Richmond, VA 23298 Ph: (804) 828-4860 |
News Archive
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress. Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C.
iPierian, Inc., the leading biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, today announced the closing of a $22 million Series B equity financing. The financing round was led by new investor Google Ventures, and was joined by Mitsubishi UFJ Capital and ATEL Ventures. All current investors also participated, including: Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital.
Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.
› Verified 2 days ago
Robert Weisberger, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Dr. Michael Ferebee, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1602 Skipwith Rd, Richmond, VA 23229 Phone: 757-329-3754 | |
James R Shefferly, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Jeffry A Zimmerman, P.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, St Francis Emergency Department, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Shawn M Borich, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Rockbridge St Ste 103, Richmond, VA 23230 Phone: 804-386-0200 | |
Tamera Barnes, MD, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7101 Jahnke Rd, Richmond, VA 23225 Phone: 804-330-2000 | |
Dr. Kevin James Noreika, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1401 Johnston Willis Dr, Richmond, VA 23235 Phone: 804-330-2277 |